鲍曼不动杆菌在烧伤患者中分离率和耐药率日益严峻，多重耐药鲍曼不动杆菌的广泛流行已严重威胁了烧伤患者的生命安全。噬菌体治疗是耐药细菌感染的治疗方向之一，我们前期筛选到一株具有良好应用前景的多重耐药鲍曼不动杆菌的裂解性噬菌体Abp1。阻碍噬菌体治疗应用的障碍之一是其基因组较大，可能携带对机体有潜在威胁的基因。为了进一步研究Abp1的基因组功能，并获得一个小型化的噬菌体Abp1’，本研究计划首先运用CRISPR-Cas9技术对Abp1的16个可能的非必需基因逐一敲除和功能研究；再整合所有必需基因获得一个基因组更小的噬菌体Abp1’；最后通过动物实验分析Abp1’的安全性和应用前景。由于缺乏有效的筛选标记，传统同源重组技术编辑噬菌体基因效率较低，本技术的构建可为鲍曼不动杆菌噬菌体的基因功能研究提供一个高效的编辑平台。同时，也为其他噬菌体基因编辑和功能研究提供参考，进而推进噬菌体治疗的临床应用。

The isolation rate of Acinetobacter baumannii increased rapidly, with the resistance to antibiotics also extended quickly. Multi-drug resistant Acinetobacter baumannii is a big threat to burn patients. As a potential weapon against drug resistant pathogens, phage therapy attracted more and more attention. Previously, we isolated a lytic phage Abp1, which shows good properties as anti-microbial drugs. Abp1 exhibits high thermal and pH stability. In both local and systemic A. baumannii infection mouse models, Abp1 treatment exhibits good therapeutic effects. One obstacle of phage therapy is huge genome of bacteriophage, which is a potential risk to human body. To obtain a smaller and safe phage, we use CRISPR-Cas9 technology to investigate genes of Abp1 in the first step. Second, combine all the essential genes to get a smaller phage Abp1’. Last, test the safety of Abp1’ with animal model. With the project, we will build an efficiency platform for phage genome modification and phage gene function investigation in Acinetobacter baumannii. At the same time, it can provide a model for phage genome modification and phage gene function investigation for other phage species and promote phage therapy.